Fourth-generation autologous CAR-T product shows efficacy for pretreated lymphoma
Click Here to Manage Email Alerts
NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy showed encouraging early efficacy among heavily pretreated patients with CD19-positive non-Hodgkin lymphoma, according to study results.
The fourth-generation CAR-T product — huCART19-IL18 — also exhibited a manageable safety profile, findings of a first-in-human study presented at ASH Annual Meeting and Exposition showed.
Healio spoke with researcher Jakub Svoboda, MD, associate professor of medicine at Hospital of the University of Pennsylvania, about the findings, their potential implications and next steps in research.
Collapse
Svoboda J, et al. Abstract 2016. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Click Here to Manage Email Alerts